Ranbaxy Pharmaceuticals ties up with Zenotech
Gurgaon, June 7: Ranbaxy Pharmaceuticals (RPI), a wholly owned subsidiary of leading pharmaceutical company Ranbaxy Laboratories Ltd (RLL), today announced that it has entered into an agreement with Hyderabad-based Zenotech Laboratories Ltd.
According to the agreement, Zenotech Labs will develop submit and manufacture a total of 11 oncology products, which Ranbaxy will market as generic formulations in the US and Canada under its label.
''This strategic initiative by RPI will establish our presence in the therapeutic arena by offering a basket of products in the US and Canadian markets that has breath and depth in the management of patients diagnosed with cancer. This agreement helps reinforce our position as a provider of high quality generic medicines that will be available at affordable prices,'' Ranbaxy President (Corporate Development) Dipak Chattraj said.
''This relationship brings together the strengths of the two companies and accelerates Zenotech Labs's ability to develop products which are specifically intended for these North American markets that continue to have clinical value to patients and prescribers,'' said Zenotech Labs CEO Dr Jayaram Chigurupati.
Zenotech is a specialty generic injectables company with a biotech core. It has research and development facilities in India and in the US.